Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
First approval using a new FDA process to speed up cancer drug reviews.
CDK4/6 inhibitor plus hormone therapy extends progression-free survival for younger women.
Talazoparib may offer an additional option for women with BRCA gene mutations.
SABCS17 study shows that losing 5 percent of body weight reduced cancer risk by 12 percent.
Direct action and legislative advocacy groups demand more awareness and research on metastatic breast cancer.
Reducing the side effects of aromatase inhibitors may help women stay on treatment.
Keytruda may restore immune function in some women who develop resistance to Herceptin.
World’s largest breast cancer conference celebrates 40 years.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.